

**GOVERNMENT OF INDIA
MINISTRY OF HEALTH AND FAMILY WELFARE
DEPARTMENT OF HEALTH AND FAMILY WELFARE**

**RAJYA SABHA
UNSTARRED QUESTION NO.3154
TO BE ANSWERED ON 23RD MARCH, 2021**

SUCCESS RATIO OF COVISHIELD VACCINE

3154 SHRI SANJAY RAUT:

Will the Minister of **HEALTH AND FAMILY WELFARE** be pleased to state:

- (a) the success ratio of Covishield developed by Serum Institute and its impacts on human health
- (b) the number of doses of vaccine against the virus that have been delivered to healthcare centers and the number of people vaccinated so far in various parts of the country
- (c) whether Government is considering to increase the volumes of vaccines with the help of private sectors and
- (d) if so, the details thereof indicating any timeframe that has been fixed for completing the vaccination programme in the country?

**ANSWER
THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND
FAMILY WELFARE
(SHRI ASHWINI KUMAR CHOUBEY)**

(a): As per New Drugs and Clinical Trials Rules, 2019 (ND & CT Rules 2019) under Drugs and Cosmetics Act, 1940 and in light of urgent need due to COVID pandemic in the country, Central Drugs Standard Control Organisation (CDSCO) in consultation with Subject Expert Committee (SEC) has granted permission to manufacture the COVID-19 vaccines of Serum Institute of India.

M/s Serum Institute of India Pvt., Ltd. Pune had submitted safety immunogenicity & efficacy data of phase II/III clinical trials of AstraZeneca vaccine carried out in UK, Brazil and South Africa along with the safety & immunogenicity data from the ongoing Phase II/III clinical trial in the country. The Subject Expert Committee (SEC) of CDSCO reviewed the proposal of restricted emergency use along with above details and the data received. The Medicines and Healthcare products Regulatory Agency (MHRA) approval for AstraZeneca vaccine on 30.12.2020 along with its conditions/restrictions was also reviewed by the committee.

The committee noted that the safety & immunogenicity data presented by the firm from the Indian study is comparable with that of the overseas clinical trial data.

Based on the recommendations of SEC, CDSCO granted permission to Serum Institute of India to manufacture COVISHIELD vaccine for restricted use in emergency situation with various conditions/restrictions

(b): As on 17.03.2021, total 7.06 crore doses of COVID-19 vaccine have been supplied to States/UTs. A total of 3.71 crore doses have been administered across the country, which includes 1.22 crore doses to Health Care Workers (75.86 lakh as 1st dose and 46.32 lakh as 2nd dose), 96.25 lakh doses to Frontline Workers (77.16 as 1st dose and 19.09 lakh as 2nd dose) and 1.53 crore doses as 1st dose to people aged 60 years & more and those aged between 45-59 years with 20 specified comorbidities.

(c) & (d): The COVID-19 vaccination is an ongoing and dynamic process, which is being expanded to include beneficiary groups as prioritized by National Expert Group on Vaccine Administration for COVID-19 (NEGVAC). In view of the dynamic and evolving nature of COVID-19 pandemic and inclusion of private COVID-19 Vaccination Centres, no fixed timeline at present can be indicated for the completion of vaccination drive.